{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:28:59Z","timestamp":1787758139988,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The management patterns for chemotherapy-associated nausea and vomiting (CANV) in Sub-Saharan African settings have not been previously reported. The objectives of this study were to describe the prescribing pattern of antiemetics for CANV, to assess their adherence to guidelines, and to determine the occurrence of CANV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>This was a cross-sectional study, with data extracted from the records of adult patients who received chemotherapy from 2015 to 2018 at Jos University Teaching Hospital, Nigeria. The National Comprehensive Cancer Network Harmonized Guidelines\u2122 for Sub-Saharan Africa for Antiemesis Version 3.2018 was used to determine the extent of guideline adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Records of 165 patients were analyzed. Majority of the patients (76.4%, n = 126) received moderate-to-high emetic risk intravenous (IV) chemotherapy. Out of 129 antiemetic prescriptions for acute-phase prophylaxis, ondansetron (75.2%), corticosteroids (61.2%), and promethazine (24.8%) were the most prescribed agents. In the delayed phase, 50 patients received prophylactic antiemetics in the order of corticosteroids, ondansetron, and promethazine at 74%, 34%, and 26%, respectively. Guideline adherence was low for the acute-phase (23.6%), delayed-phase (20.6%), and overall period (17.6%). Among inpatients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 85), occurrences of nausea were negligible, whereas acute vomiting (9%) and delayed vomiting (15%) levels were considerable. Not receiving highly emetogenic IV chemotherapy was associated with significantly lower odds for nausea or vomiting occurrence, odds ratio 0.228 (95% confidence interval 0.054\u20130.967).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Antiemetic guideline adherence was low due to antiemetic under-prescribing. A few nausea and vomiting events were recorded predominantly among patients who received highly emetogenic IV chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_87_20","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:27:39Z","timestamp":1657067259000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Chemotherapy-Associated Nausea and Vomiting"],"prefix":"10.4103","volume":"21","author":[{"given":"Kelvin Mogesa","family":"Manyega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Nasara","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okunlola Charity","family":"Rotkangmwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell P.","family":"Dapar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240831","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/DHPS.S116924","article-title":"Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: A cross-sectional study","volume":"8","author":"Belachew","year":"2016","journal-title":"Drug Healthc Patient Saf"},{"key":"R2-4-20240831","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-4-20240831","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.1985.3.10.1379","article-title":"Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin","volume":"3","author":"Kris","year":"1985","journal-title":"J Clin Oncol"},{"key":"R4-4-20240831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198300251-00002","article-title":"Nausea and vomiting as major complications of cancer chemotherapy","volume":"25 Suppl 1","author":"Laszlo","year":"1983","journal-title":"Drugs"},{"key":"R5-4-20240831","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00520-016-3332-x","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents","volume":"25","author":"Jordan","year":"2017","journal-title":"Support Care Cancer"},{"key":"R7-4-20240831","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-4-20240831","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.1997.15.8.2966","article-title":"Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy","volume":"15","author":"Lofters","year":"1997","journal-title":"J Clin Oncol"},{"key":"R9-4-20240831","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"R10-4-20240831","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"R11-4-20240831","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaoncol.2016.2530","article-title":"Changes in antiemetic overuse in response to choosing wisely recommendations","volume":"3","author":"Encinosa","year":"2017","journal-title":"JAMA Oncol"},{"key":"R12-4-20240831","first-page":"1","article-title":"Oncology guidelines usage in a low- and middle-income country","volume":"4","author":"Ismaila","year":"2018","journal-title":"J Glob Oncol"},{"key":"R13-4-20240831","first-page":"9","article-title":"Practical issues in calculating the sample size for prevalence studies","volume":"1","author":"Naing","year":"2006","journal-title":"Arch Orofac Sci"},{"key":"R14-4-20240831","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/ijmpo.ijmpo_116_17","article-title":"A study on utilization and evaluation of antiemetics in chemotherapy-induced nausea and vomiting","volume":"38","author":"Baburaj","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R15-4-20240831","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.4143\/crt.2015.309","article-title":"Clinical practices and outcomes on chemotherapy-induced nausea and vomiting management in South Korea: comparison with Asia-pacific data of the pan Australasian chemotherapy induced emesis burden of illness study","volume":"48","author":"Lee","year":"2016","journal-title":"Cancer Res Treat"},{"key":"R16-4-20240831","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bulcan.2016.03.009","article-title":"Region-wide professional practice evaluation with regards to antiemetic prescription into chemotherapy-induced nausea and vomiting","volume":"103","author":"Tavernier","year":"2016","journal-title":"Bull Cancer"},{"key":"R17-4-20240831","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/TCRM.S133820","article-title":"Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: A prospective observational study","volume":"13","author":"Vazin","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R18-4-20240831","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1200\/JOP.2016.019448","article-title":"Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India","volume":"13","author":"Patil","year":"2017","journal-title":"J Oncol Pract"},{"key":"R19-4-20240831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050312118767234","article-title":"A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting","volume":"6","author":"Alamri","year":"2018","journal-title":"SAGE Open Med"},{"key":"R20-4-20240831","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2016.4096","article-title":"Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk","volume":"3","author":"Okuyama","year":"2017","journal-title":"JAMA Oncol"},{"key":"R22-4-20240831","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","article-title":"Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study","volume":"23","author":"Escobar","year":"2015","journal-title":"Support Care Cancer"},{"key":"R23-4-20240831","first-page":"877","article-title":"Control of nausea and vomiting in patients receiving anthracycline\/cyclophosphamide chemotherapy for breast cancer","volume":"38","author":"Nawa-Nishigaki","year":"2018","journal-title":"Anticancer Res"},{"key":"R25-4-20240831","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_87_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:03:03Z","timestamp":1787756583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_87_20"}},"subtitle":["A Cross-Sectional Survey of Occurrence and Management Patterns at Jos University Teaching Hospital, Nigeria"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_87_20","relation":{},"ISSN":["1596-3519"],"issn-type":[{"value":"1596-3519","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}